Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : Disease save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.9 0.86% 590K
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.385 1.84% 1.5M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.385 1.84% 1.5M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $30.475 1.38% 360K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $107.91 0.78% 1.7M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.5605 -2.49% 100K
|
|
| O: 7.64%
H: 21.41%
C: 1.07%
disease kidney cholesterol approval trial therapeutics diabetic
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 1.0%
H: 1.41%
C: -0.25%
disease pneumococcal children
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.31 2.44% 2.2M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2024-02-13 (Crawled : 09:00) - biospace.com/
VRTX | $405.165 1.31% 390K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
first disease cell treatment
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Published: 2024-02-13 (Crawled : 08:00) - globenewswire.com
VRTX | $405.165 1.31% 390K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
CRSP | News M | $56.9 2.23% 850K
|
Health Technology
|
| O: -5.3%
H: 3.85%
C: 0.54%
first disease cell treatment
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
SGMO | News | $0.535 4.88% 1.8M
|
Health Technology
|
| O: 8.46%
H: 35.96%
C: 29.21%
st-920 fda disease approval prime ema therapeutics potential
Johnson &Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANGO | $6.115 -2.32% 220K
|
Health Technology
|
| O: 1.66%
H: 0.33%
C: -2.28%
fda disease treat clearance
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
BLUE | $0.9963 4.48% 3.5M
|
Health Technology
|
| O: 6.03%
H: 8.43%
C: -43.92%
disease cell commercial therapy
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
BLUE | $0.9963 4.48% 3.5M
|
Health Technology
|
| O: 6.03%
H: 8.43%
C: -43.92%
fda disease approval cell
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
VRTX | $405.165 1.31% 390K
|
Health Technology
|
| O: 0.01%
H: 0.1%
C: -1.09%
CRSP | News M | $56.9 2.23% 850K
|
Health Technology
|
| O: 1.22%
H: 8.3%
C: -9.19%
fda crispr disease approval cell treatment therapeutics
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $15.75 4.44% 170K
|
Manufacturing
|
| O: 3.35%
H: 7.88%
C: -6.03%
fda rare drug disease program
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
IGXT | $0.1699 44K
|
Manufacturing
|
| O: 7.74%
H: 1.85%
C: -0.96%
versafilm disease parkinson's approval montelukast trial phase 2
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
ETON | $3.37 3.69% 14K
|
Health Technology
|
| O: 0.0%
H: 4.86%
C: 3.32%
disease acquisition pharmaceuticals
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.21 41.67% 5.6M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.